Thr73

Site Information
LLRIRPLtPVSDSGD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 456008

In vivo Characterization
Methods used to characterize site in vivo:	[32P] bio-synthetic labeling ( 2 ) , mass spectrometry ( 1 ) , mutation of modification site ( 2 )
Relevant cell line - cell type - tissue:	HepG2 (hepatic) ( 1 )

Downstream Regulation
Effects of modification on TIEG2:	molecular association, regulation ( 2 )
Inhibit interaction with:	SIN3A (human) ( 2 )

References
1	Possemato A (2009) CST Curation Set: 7408; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986 Curated Info
2	Ellenrieder V, Zhang JS, Kaczynski J, Urrutia R (2002) Signaling disrupts mSin3A binding to the Mad1-like Sin3-interacting domain of TIEG2, an Sp1-like repressor. EMBO J 21, 2451-60 12006497 Curated Info

References

Possemato A (2009) CST Curation Set: 7408; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

Ellenrieder V, Zhang JS, Kaczynski J, Urrutia R (2002) Signaling disrupts mSin3A binding to the Mad1-like Sin3-interacting domain of TIEG2, an Sp1-like repressor. EMBO J 21, 2451-60
12006497 Curated Info